Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Open access

Abstract

BACKGROUND: The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). Positive impacts of LDX on health-related quality of life and functional impairment have previously been demonstrated in a 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in Europe. Maintenance of these broad benefits, as well as symptomatic control, is a key goal of long-term management of ADHD. OBJECTIVE: Secondary objectives of this multinational study in children and adolescents with ADHD were to assess the long-term maintenance of effectiveness of LDX in improving health-related quality of life and reducing functional impairment, as gauged using the Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE: PRF) and the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P), respectively. METHODS: Patients aged 6-17 years with diagnosed ADHD and a baseline ADHD Rating Scale IV total score of at least 28 were enrolled from the previous European study and from US sites. Patients who completed an open-label LDX treatment period of at least 26 weeks were randomized (1:1) to continue on their optimized dose of LDX or to switch to placebo for a 6-week, double-blind, withdrawal period. Parents completed CHIP-CE: PRF and WFIRS-P questionnaires at weeks 0, 8 and 26 of the open-label period and at weeks 0 and 6 of the randomized-withdrawal period, or at early termination. The endpoint of each period was defined as the last visit with valid data. Effect sizes were the difference (LDX minus placebo) in least-squares (LS)-mean change from baseline to endpoint divided by root-mean-square error. P values were nominal and not adjusted for multiple comparisons. RESULTS: The open-label and randomized full analysis sets comprised 262 and 153 (LDX n = 76; placebo n = 77) patients, respectively. Mean pretreatment CHIP-CE: PRF T-scores were more than one standard deviation below the normative mean in four of the five domains, and there was significant improvement across all domains from baseline to endpoint of the open-label period. In the randomized-withdrawal period, LS-mean CHIP-CE: PRF T-scores deteriorated in all domains in the placebo group, but not in the LDX group. Compared with placebo, the effect of LDX was significant in the Risk Avoidance (effect size 0.829; p < 0.001), Achievement (0.696; p < 0.001) and Satisfaction (0.636; p < 0.001) domains. Mean pretreatment WFIRS-P scores were lowest in the Family domain and the Learning and School domain. WFIRS-P total score and scores in all domains improved significantly from baseline to endpoint of the open-label period. In the randomized-withdrawal period, LS-mean scores deteriorated in the placebo group but not in the LDX group. Compared with placebo, the effect of LDX was significant in the Family, Learning and School, and Risky Activities domains and in total (effect size 0.908; p < 0.001). CONCLUSIONS: Using parent-rated instruments, long-term maintenance of the beneficial effect of LDX in multiple domains of health-related quality of life and functional impairment was demonstrated by comparison of treatment continuation and withdrawal under randomized, double-blind, placebo-controlled conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-014-0193-z

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 SPD489-326 study design. CHIP-CE: PRF and WFIRS-P assessments were performed at the visits shown boxed, and/or at an early termination visit attended by patients who discontinued the study. aFor directly recruited patients only; other patients completed screening and washout as part of SPD489-325, the previous European, phase III study. bScreening and washout occurred 1–6 weeks before visit 1 for directly recruited patients. cSee Table 1 for definitions of baseline and endpoint in the open-label and randomized-withdrawal periods. dExtended dose-maintenance phase for patients enrolled under the original protocol. These patients may have attended one or more additional visits (shown in grey) before entering the fixed-dose period. eItalicized numbers show weeks of the randomized-withdrawal period. CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, R revised, WFIRS-P Weiss Functional Impairment Rating Scale-Parent Report
Fig. 1 SPD489-326 study design. CHIP-CE: PRF and WFIRS-P assessments were performed at the visits shown boxed, and/or at an early termination visit attended by patients who discontinued the study. aFor directly recruited patients only; other patients completed screening and washout as part of SPD489-325, the previous European, phase III study. bScreening and washout occurred 1–6 weeks before visit 1 for directly recruited patients. cSee Table 1 for definitions of baseline and endpoint in the open-label and randomized-withdrawal periods. dExtended dose-maintenance phase for patients enrolled under the original protocol. These patients may have attended one or more additional visits (shown in grey) before entering the fixed-dose period. eItalicized numbers show weeks of the randomized-withdrawal period. CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, R revised, WFIRS-P Weiss Functional Impairment Rating Scale-Parent ReportCC BY-NC · PubMed Central
Fig. 2 CHIP-CE: PRF T-scores during the open-label period (n = 262). a Mean T-scores at open-label baseline and histogram showing mean change from open-label baseline to endpoint for CHIP-CE: PRF domains and subdomains. Error bars show 95 % CIs. Positive changes indicate improved HRQoL. ***p < 0.001, **p < 0.01, change at endpoint versus baseline (two-sided t test). P values are nominal and were not adjusted for multiple comparisons. b Mean CHIP-CE: PRF domain T-scores at baseline (BL), endpoint (EP), visit 6 (V6 8 weeks) and visit 3R (V3R ≥26 weeks) of the open-label period. Error bars show 95 % confidence intervals. These data were not subjected to statistical testing. Numbers of observations (n) are shown for each data point. A T-score of 43 or below indicates poor HRQoL in a domain or subdomain; a T-score of 57 or above indicates excellent HRQoL [20]. The horizontal axis is positioned at the normative mean (T-score of 50). BL baseline, CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, CI confidence interval, EP endpoint, HRQoL health-related quality of life, R revised, SD standard deviation, V visit
Fig. 2 CHIP-CE: PRF T-scores during the open-label period (n = 262). a Mean T-scores at open-label baseline and histogram showing mean change from open-label baseline to endpoint for CHIP-CE: PRF domains and subdomains. Error bars show 95 % CIs. Positive changes indicate improved HRQoL. ***p < 0.001, **p < 0.01, change at endpoint versus baseline (two-sided t test). P values are nominal and were not adjusted for multiple comparisons. b Mean CHIP-CE: PRF domain T-scores at baseline (BL), endpoint (EP), visit 6 (V6 8 weeks) and visit 3R (V3R ≥26 weeks) of the open-label period. Error bars show 95 % confidence intervals. These data were not subjected to statistical testing. Numbers of observations (n) are shown for each data point. A T-score of 43 or below indicates poor HRQoL in a domain or subdomain; a T-score of 57 or above indicates excellent HRQoL [20]. The horizontal axis is positioned at the normative mean (T-score of 50). BL baseline, CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, CI confidence interval, EP endpoint, HRQoL health-related quality of life, R revised, SD standard deviation, V visitCC BY-NC · PubMed Central
Fig. 3 Statistical analysis of changes in CHIP-CE: PRF T-scores from baseline to endpoint of the randomized-withdrawal period (n = 153). Histogram shows LS-mean change in CHIP-CE: PRF domain and subdomain T-scores from baseline to endpoint of the randomized-withdrawal period. Error bars show 95 % CIs. Effect size is the difference in LS-mean change (LDX minus placebo) divided by root-mean-square error. Positive changes indicate improved health-related quality of life. *p < 0.05, **p < 0.01, ***p < 0.001, change from baseline to endpoint (ad hoc analysis); † p < 0.05, †† p < 0.01, ††† p < 0.001, LDX change versus placebo change (prespecified analysis). P values are nominal and were not adjusted for multiple comparisons. CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, LDX lisdexamfetamine dimesylate, LS least-squares
Fig. 3 Statistical analysis of changes in CHIP-CE: PRF T-scores from baseline to endpoint of the randomized-withdrawal period (n = 153). Histogram shows LS-mean change in CHIP-CE: PRF domain and subdomain T-scores from baseline to endpoint of the randomized-withdrawal period. Error bars show 95 % CIs. Effect size is the difference in LS-mean change (LDX minus placebo) divided by root-mean-square error. Positive changes indicate improved health-related quality of life. *p < 0.05, **p < 0.01, ***p < 0.001, change from baseline to endpoint (ad hoc analysis); † p < 0.05, †† p < 0.01, ††† p < 0.001, LDX change versus placebo change (prespecified analysis). P values are nominal and were not adjusted for multiple comparisons. CHIP-CE: PRF Child Health and Illness Profile-Child Edition: Parent Report Form, LDX lisdexamfetamine dimesylate, LS least-squaresCC BY-NC · PubMed Central
Fig. 4 WFIRS-P scores during the open-label period (n = 262). a Mean scores at open-label baseline and histogram showing mean change from open-label baseline to endpoint for WFIRS-P domain and total scores. Error bars show 95 % confidence intervals. Negative changes indicate reduced functional impairment. ***p < 0.001, **p < 0.01, change at endpoint versus baseline (two-sided t test). P values are nominal and were not adjusted for multiple comparisons. b Mean WFIRS-P domain and total scores at baseline (BL), endpoint (EP), visit 6 (V6 8 weeks) and visit 3R (V3R ≥26 weeks) of the open-label period. Error bars show 95 % CIs. These data were not subjected to statistical testing. Numbers of observations (n) are shown for each data point. Higher scores indicate more severe functional impairment. BL baseline, CI confidence interval, EP endpoint, R revised, SD standard deviation, V visit, WFIRS-P Weiss Functional Impairment Rating Scale-Parent Report
Fig. 4 WFIRS-P scores during the open-label period (n = 262). a Mean scores at open-label baseline and histogram showing mean change from open-label baseline to endpoint for WFIRS-P domain and total scores. Error bars show 95 % confidence intervals. Negative changes indicate reduced functional impairment. ***p < 0.001, **p < 0.01, change at endpoint versus baseline (two-sided t test). P values are nominal and were not adjusted for multiple comparisons. b Mean WFIRS-P domain and total scores at baseline (BL), endpoint (EP), visit 6 (V6 8 weeks) and visit 3R (V3R ≥26 weeks) of the open-label period. Error bars show 95 % CIs. These data were not subjected to statistical testing. Numbers of observations (n) are shown for each data point. Higher scores indicate more severe functional impairment. BL baseline, CI confidence interval, EP endpoint, R revised, SD standard deviation, V visit, WFIRS-P Weiss Functional Impairment Rating Scale-Parent ReportCC BY-NC · PubMed Central
Fig. 5 Statistical analysis of changes in WFIRS-P scores from baseline to endpoint of the randomized-withdrawal period (n = 153). Histogram shows LS-mean change in WFIRS-P domain and total scores from baseline to endpoint of the randomized-withdrawal period. Error bars show 95 % CIs. Effect size is the difference in LS-mean change (LDX minus placebo) divided by root-mean-square error. Positive changes indicate worsened functional impairment. *p < 0.05, **p < 0.01, ***p < 0.001, change from baseline to endpoint (ad hoc analysis); † p < 0.05, †† p < 0.01, ††† p < 0.001, LDX change versus placebo change (prespecified analysis). P values are nominal and were not adjusted for multiple comparisons. LDX lisdexamfetamine dimesylate, LS least-squares, WFIRS-P Weiss Functional Impairment Rating Scale-Parent Report
Fig. 5 Statistical analysis of changes in WFIRS-P scores from baseline to endpoint of the randomized-withdrawal period (n = 153). Histogram shows LS-mean change in WFIRS-P domain and total scores from baseline to endpoint of the randomized-withdrawal period. Error bars show 95 % CIs. Effect size is the difference in LS-mean change (LDX minus placebo) divided by root-mean-square error. Positive changes indicate worsened functional impairment. *p < 0.05, **p < 0.01, ***p < 0.001, change from baseline to endpoint (ad hoc analysis); † p < 0.05, †† p < 0.01, ††† p < 0.001, LDX change versus placebo change (prespecified analysis). P values are nominal and were not adjusted for multiple comparisons. LDX lisdexamfetamine dimesylate, LS least-squares, WFIRS-P Weiss Functional Impairment Rating Scale-Parent ReportCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Riley AW, Robertson JA, Forrest CB, Green BF, Rebok GW, Starfield B. Technical manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0). Baltimore: Johns Hopkins University; 2001.

Cited by

See all 53

Metadata

Authors
Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R.
Affiliations
  • Heidelberg University (DE)
  • Drottning Silvias barn- och ungdomssjukhus (SE)
  • Hôpital Robert-Debré (FR)
  • University of Cagliari (IT)
  • Takeda (United States) (US)
  • University of Dundee (GB)
Corresponding author
Banaschewski, Tobias
Venue
CNS Drugs
Published
2014-08-20
Volume
28
Issue
12
Pages
1191-1203
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W2045793565
Cited by
41
References
31
Citations by year
2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 7 · 2017: 6 · 2016: 4 · 2015: 5
FWCI
3.81
Type
journal article
Language
en
Open access
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
  • UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Vertex Pharmaceuticals
  • University of Oxford
  • Vifor Pharma
  • H. Lundbeck A/S
  • Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, children and adolescents, health-related quality of life, functional disability, Weiss Functional Impairment Rating Scale, parent-reported outcomes, ADHD symptoms, treatment efficacy and tolerability
MeSH terms
Lisdexamfetamine Dimesylate, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Dextroamphetamine, Double-Blind Method, Europe, Female, Humans, Male, Psychiatric Status Rating Scales, Psychotropic Drugs, Quality of Life, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1007/s40263-014-0193-z
The paper
Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R. (2014). Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. https://doi.org/10.1007/s40263-014-0193-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.